Here are five things to know:
• Integra Lifesciences has received a consensus rating of “Buy” from the seven analysts that are covering the company.
• The company has a one-year low of $42.50 and a one-year high of $61.26.
• The stock’s 50-day moving average is $57.
• The stock’s 200-day moving average is $51.
• The company has a market cap of $1.97 billion.
More articles on devices:
NuVasive, Medtronic patent saga continues — 5 key updates
InVivo goes from illiquid to a top-traded stock: 5 key notes
6 key notes on Mazor Robotics’ short interest decline
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
